Journal of the American Academy of Dermatology

Standard blood tests can help physicians predict the risk of mortality in patients with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These findings may facilitate earlier interventions and enable more personalized treatment strategies for this severe cutaneous adverse reaction (SCAR).

Two rare skin conditions with similar symptoms can be mistaken for each other, so a scoring system has been formulated to aid physicians in distinguishing two diseases